BioNTech Pharma (BNTX): Broker Consensus Forecast
The BioNTech SE (BNTX) price chart reflects the dynamics of the biotech sector, where the company is redirecting resources toward the development of personalized mRNA-based tumor therapies. The current metric stands at 115.19, although the business faces declining revenues from COVID-19 products and uncertainty surrounding clinical trials. Amidst fierce competition with capital-intensive behemoths, the risk of acquisition or losing the technological race remains significant.
Analytical breakdowns for BioNTech Group (BNTX)
- current price and projected stock value:
- stock exchange capitalization data:
- business book valuation details:
- business debt structure and liquidity details:
Aggregate Debt to Equity BioNTech SE|BNTX - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital BioNTech Pharma|BNTX - Company Aggregate Debts|Debts to Book Capitalization BioNTech Group|BNTX - Company Long-Term Debt|Company Short-Term Loans and Borrowings BioNTech|Quick Liquidity Indicator biontech.de
- earnings and market ratios statistics:
BNTX - Net Profit|Projected Future Earnings BioNTech SE|BNTX - Price to Earnings Ratio|Future Price to Earnings Multiple BioNTech Inc.|BNTX - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio BioNTech Group|BNTX - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months BioNTech|BNTX - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months biontech.de|BNTX - Net earnings per share growth this year|Earnings growth forecast for next year BioNTech SE
General company analysis:BNTX biontech.de
The absence of a commercial drug portfolio deprives BioNTech SE (BNTX) of pricing power, turning R&D investments into a high-risk zone. The average analyst target for the stock on GURU.Markets aggregates expert expectations for the asset's fair value, allowing investors to compare the market price with the company's fundamental potential amid a lack of stable cash flows and a dependence on future discoveries.
Competitors of BioNTech SE
Price Target Chart ARGX (argenx.com)|Price Target Chart Abivax ABVX|ADMA: Broker Consensus Forecast|PTGX: Consensus Target|Immunovant Therapeutics - Analyst Forecast Prices|KNSA (Kiniksa Pharmaceuticals) - Consensus Target|Broker Consensus Forecast GRFS|Price Target Chart Adaptive Biotechnologies Corporation|Celldex Therapeutics Inc - Forecast Levels Chart|Analyst Consensus Forecast AUPH|BCRX (BioCryst Corp) - Fair Value Consensus|Analyst Consensus Forecast VERA (Vera Therapeutics, Inc.)|Analyst Consensus Forecast dianthustx.com DNTH|PHVS - Price Target Chart|Fair Value Consensus ABCL (abcellera.com)|Tourmaline Corp (TRML) - Price Target Chart|Consensus Target Precigen Corp|PHAR (Pharming Group N.V.) - Analyst Consensus Forecast|Analyst Consensus Forecast nektar.com|Consensus Target UPB (Upstream Bio)|ZBIO (Zenas Bio) - Fair Value Consensus|Analyst Consensus Forecast IMNM (Immunome Corp)|Analyst Median Target Gossamer Bio Corp. (GOSS)|KALV - Price Target Chart|septerna.com (SEPN) - Consensus Target|Pieris Pharmaceuticals, Inc. (PVLA) - Price Target Chart|Consensus Target Savara Inc|Consensus Target RIGL|Analyst Consensus Forecast AnaptysBio Inc.|Price Target Chart Astria Therapeutics (ATXS)|engene.com - Broker Consensus Forecast|Analyst Consensus Forecast RAPT (RAPT Therapeutics, Inc.)|Aerovate Therapeutics, Inc. (JBIO) - Average Forecast Price|Aclaris - Analyst Consensus Forecast|KYTX: Price Target Chart|TLSA: Analyst Consensus Forecast|CABA - Analyst Median Target|Price Target Chart Ventyx Biosciences, Inc.|Average Forecast Price Theratechnologies, Inc. THTX|Price Target Chart Avalo Therapeutics Inc. (AVTX)|Eledon Pharmaceuticals, Inc - Broker Consensus Forecast|Agenus - Consensus Target|Analyst Forecast Prices CLYM (climbbio.com)|Zura Bio Limited - Analyst Consensus Forecast|Average Forecast Price aTyr Pharma Inc|ADAG: Analyst Consensus Forecast|Consensus Target Ikena Oncology|STTK (Shattuck Labs Inc) - Analyst Consensus Forecast|EQ: Fair Value Consensus|Consensus Target CNTB (Connect Biopharma)|IMUX (immunic-therapeutics.com) - Fair Value Consensus|Price Target Chart Atara Bio ATRA|Analyst Median Target InflaRx NV (IFRX)|X4 Pharmaceuticals - Analyst Consensus Forecast|Average Forecast Price Adicet Bio|CELU: Analyst Consensus Forecast|INMB (INmune Bio Inc) - Price Target Chart|Price Target Chart Barinthus Bio|Broker Consensus Forecast KZR (Kezar Life Sciences Inc)|Consensus Target SABS (SAB Biotherapeutics)|Analyst Forecast Prices AKTX|Enlivex Therapeutics Ltd. - Consensus Target|QTTB: Broker Consensus Forecast|GOVX - Price Target Chart|Forecast Levels Chart EDSA|IBIO: Analyst Consensus Forecast|Carisma Therapeutics Inc. - Fair Value Consensus|XTLB (XTL Biopharmaceuticals Ltd.) - Analyst Consensus Forecast|Analyst Consensus Forecast Bolt Bio|Price Target Chart HCW Biologics Inc. (HCWB)|APVO (aptevotherapeutics.com) - Fair Value Consensus|Price Target Chart AIM ImmunoTech AIM|ADTX - Consensus Target|GRI Bio - Analyst Consensus Forecast|XRTX - Analyst Consensus Forecast|HIND (ReShape Lifesciences) - Consensus Target|Revelation Biosciences Corp - Fair Value Consensus|INDP (Indaptus Therapeutics) - Analyst Consensus Forecast|scinai.com (SCNI) - Analyst Median Target|Price Target Chart CalciMedica, Inc. (CALI)|Consensus Target affimed.com AFMD|Price Target Chart Allakos ALLK|HOOK - Consensus Target|IGMS: Consensus Target|ITOS - Analyst Consensus Forecast|Ocean Biomedical (OCEA) - Price Target Chart|Broker Consensus Forecast TCBP|THRD (Third Harmonic Bio, Inc) - Analyst Consensus Forecast
